Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Short Interest Up 2,800.0% in July

Key Points

• Short interest in Orion OYJ Unsponsored ADR increased dramatically by 2,800.0% in July, rising from 100 shares to 2,900 shares.
• The stock price has remained relatively stable, trading at $38.43, with a market capitalization of $10.85 billion.
• Orion OYJ reported $0.33 EPS and $472.57 million in revenue for the last quarter, with analysts predicting an EPS of 1.18 for the current year.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 2,900 shares, anincreaseof2,800.0% from the July 15th total of 100 shares. Based on an average daily trading volume, of 1,600 shares, the short-interest ratio is currently 1.8 days. Approximately0.0% of the shares of the stock are short sold. Approximately0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,600 shares, the short-interest ratio is currently 1.8 days.

Orion OYJ Price Performance

Shares of OTCMKTS ORINY traded up $0.0125 during midday trading on Tuesday, reaching $39.85. 253 shares of the stock traded hands, compared to its average volume of 565. The stock has a market capitalization of $11.25 billion, a PE ratio of 27.11 and a beta of 0.10. The company's 50 day moving average is $38.54 and its 200 day moving average is $32.81. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.86 and a quick ratio of 1.05. Orion OYJ has a one year low of $21.95 and a one year high of $41.60.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last issued its quarterly earnings data on Friday, July 18th. The company reported $0.33 EPS for the quarter. Orion OYJ had a net margin of 22.61% and a return on equity of 38.68%. The business had revenue of $472.57 million during the quarter. On average, equities research analysts anticipate that Orion OYJ will post 1.18 earnings per share for the current year.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.